Jazz Pharmaceuticals plc (J7Z) — Working Capital to Net Assets Ratio
Jazz Pharmaceuticals plc (J7Z) has a Working Capital to Net Assets ratio of 51.6% as of March 2026. Working capital of €2.34 Billion (current assets of €4.58 Billion minus current liabilities of €2.25 Billion) is measured against net assets of €4.53 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Jazz Pharmaceuticals plc balance sheet independence to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Jazz Pharmaceuticals plc Working Capital to Net Assets (2013–2025)
This chart shows how Jazz Pharmaceuticals plc's Working Capital to Net Assets ratio has evolved across 13 annual periods from 2013 to 2025. As of March 2026, the ratio stands at 51.6%, reflecting working capital of €2.34 Billion against net assets of €4.53 Billion EUR. Check Jazz Pharmaceuticals plc (J7Z) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Jazz Pharmaceuticals plc (2013–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Jazz Pharmaceuticals plc from 2013 to 2025, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see J7Z market cap.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 44.5% | €1.92 Billion | €4.32 Billion | €4.17 Billion | €2.24 Billion | ▼ -43.2 pp |
| 2024 | 87.7% | €3.59 Billion | €4.09 Billion | €4.63 Billion | €1.04 Billion | ▲ +36.9 pp |
| 2023 | 50.8% | €1.90 Billion | €3.74 Billion | €3.44 Billion | €1.54 Billion | ▼ -3.4 pp |
| 2022 | 54.2% | €1.67 Billion | €3.09 Billion | €2.61 Billion | €933.19 Million | ▲ +8.8 pp |
| 2021 | 45.4% | €1.80 Billion | €3.97 Billion | €2.61 Billion | €809.30 Million | ▼ -14.3 pp |
| 2020 | 59.7% | €2.19 Billion | €3.66 Billion | €2.84 Billion | €653.75 Million | ▲ +19.0 pp |
| 2019 | 40.7% | €1.27 Billion | €3.11 Billion | €1.63 Billion | €364.49 Million | ▲ +8.5 pp |
| 2018 | 32.2% | €888.52 Million | €2.76 Billion | €1.23 Billion | €345.49 Million | ▲ +7.4 pp |
| 2017 | 24.9% | €674.33 Million | €2.71 Billion | €968.28 Million | €293.95 Million | ▼ -1.3 pp |
| 2016 | 26.1% | €490.66 Million | €1.88 Billion | €748.07 Million | €257.41 Million | ▼ -38.4 pp |
| 2015 | 64.5% | €1.03 Billion | €1.60 Billion | €1.26 Billion | €226.64 Million | ▲ +6.2 pp |
| 2014 | 58.3% | €799.04 Million | €1.37 Billion | €1.02 Billion | €216.80 Million | ▲ +7.3 pp |
| 2013 | 51.0% | €660.59 Million | €1.30 Billion | €864.62 Million | €204.03 Million | — |